newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation Entered into a clinical collaboration with Merck to